NEXUS Aortic Arch Stent Graft System
Endospan , Ltd. · Decision date Jul 24, 2026
What did the FDA approve?
FDA records P250033/S002 as a supplement to PMA P250033, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 24, 2026.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250033.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 24, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250033/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- Decision code
- APPR
- Decision date
- Jul 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250033 · Original PMA
NEXUS Aortic Arch Stent Graft System
P250033/S002 received
Application receipt date recorded by FDA.
P250033/S001 · Related supplement
NEXUS Aortic Arch Stent Graft System
P250033/S002 · FDA decision
Normal 180 Day Track No User Fee
P250033/S004 · Related supplement
NEXUS Aortic Arch Stent Graft System
Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Endospan , Ltd. | PMA approval | Apr 2, 2026 | FDA | |
NEXUS Aortic Arch Stent Graft SystemP250033/S001 | Endospan , Ltd. | PMA supplement | May 20, 2026 | FDA |
NEXUS Aortic Arch Stent Graft SystemP250033/S004 | Endospan , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endospan , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Alta Meadows Rd., Alta, WY, 83414
Sources and methodology
- Original FDA record: P250033/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

